PD184352 (CI-1040)

Catalog No.S1020

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Cited by 47 Publications

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )
Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )
Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

13 Customer Reviews

The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.
Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.
a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.
Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.
Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.
After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.
The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkj4TWM2OD1yLkCyNlc3KM7:TR?=	M3vZN3NCVkeHUh?=
CHP-212	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojNTWM2OD1yLkCyPFg2KM7:TR?=	NUHPfYJrW0GQR1XS
EoL-1-cell	M3;i[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwMESxOVIh\|ryP	NUnuWWpDW0GQR1XS
DU-4475	NX\iPZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nzTGlEPTB;MD6wO\|U6QSEQvF2=	MYrTRW5ITVJ?
MMAC-SF	M3TiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMUC5O\|Qh\|ryP	MVnTRW5ITVJ?
AGS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV74NZBGUUN3ME2wMlEyPzF\|IN88US=>	MUnTRW5ITVJ?
M14	MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:5TWM2OD1yLkG1OFY5KM7:TR?=	M{PGWXNCVkeHUh?=
CP50-MEL-B	NV3TRoNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfMToZOUUN3ME2wMlE4OjV2IN88US=>	MoP4V2FPT0WU
C32	NU[3VWJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3ZNYhKSzVyPUCuNVkxPzJizszN	NEfPS\|BUSU6JRWK=
KMOE-2	NEXISXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUm3PVUh\|ryP	M3zzZXNCVkeHUh?=
A101D	NY\zVnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rOWmlEPTB;MD6yNVQh\|ryP	MmfzV2FPT0WU
KM12	MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW1cHRZUUN3ME2wMlI1ODV5IN88US=>	MY\TRW5ITVJ?
HSC-4	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMkSzPVUh\|ryP	Mn3lV2FPT0WU
NOMO-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMkW3OFIh\|ryP	MVvTRW5ITVJ?
MZ7-mel	NHfpXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTBwMk[zOEDPxE1?	NHS2b5VUSU6JRWK=
ACN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMk[3N\|ch\|ryP	MorHV2FPT0WU
MEL-HO	M2rDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1S2UWlEPTB;MD6yO\|Y2OiEQvF2=	MlzpV2FPT0WU
BHT-101	NEPMU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[wXItKSzVyPUCuNlg3ODZizszN	MWrTRW5ITVJ?
SK-MEL-28	NFP4VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2S3SGlEPTB;MD6zNFQxQSEQvF2=	NGDjS4lUSU6JRWK=
KG-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILIeYFKSzVyPUCuN\|A3PjhizszN	M1rienNCVkeHUh?=
COLO-679	M13CfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HiTGlEPTB;MD6zNlczKM7:TR?=	NFrG[FdUSU6JRWK=
SK-MEL-24	NFKwV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDCd4g{UUN3ME2wMlMzQDF\|IN88US=>	MU\TRW5ITVJ?
G-361	NUnSPWtjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwM{[3PVUh\|ryP	MmfaV2FPT0WU
KY821	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2GyfWlEPTB;MD6zO\|kyKM7:TR?=	NVS1UWdMW0GQR1XS
KASUMI-1	M3uzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILLO\|ZKSzVyPUCuN\|k6KM7:TR?=	MlrqV2FPT0WU
HL-60	M{DHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7zTWM2OD1yLkSxNVA4KM7:TR?=	NXPBZoU6W0GQR1XS
K5	NHzWVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLnNoZjUUN3ME2wMlQ{OTF5IN88US=>	M{PQ[3NCVkeHUh?=
KU812	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLiUFJzUUN3ME2wMlQ2Ojl7IN88US=>	NWLuTopYW0GQR1XS
SH-4	NFjmVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYT6UoRvUUN3ME2wMlQ3OjV4IN88US=>	MmfsV2FPT0WU
HTC-C3	NV65O4xPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DSNGlEPTB;MD60OlU{OSEQvF2=	M3\CWnNCVkeHUh?=
CP66-MEL	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDCTWM2OD1yLkS4PFA6KM7:TR?=	NILHfWJUSU6JRWK=
WM-115	MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3e1cmlEPTB;MD60PVI2PyEQvF2=	MoHEV2FPT0WU
A2780	NX\LO2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HKXGlEPTB;MD60PVgzOyEQvF2=	NIrlVphUSU6JRWK=
P12-ICHIKAWA	M4j2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoexTWM2OD1yLk[xNlIyKM7:TR?=	MVHTRW5ITVJ?
HMV-II	NV;RSphDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTBwNkS0OlUh\|ryP	MY\TRW5ITVJ?
HT-144	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrWOIpuUUN3ME2wMlY1PjV5IN88US=>	MUfTRW5ITVJ?
LB2518-MEL	NYPRT4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwN{G2N\|Ih\|ryP	NGPSWI5USU6JRWK=
NCI-SNU-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwN{W0N\|Mh\|ryP	MmT5V2FPT0WU
C2BBe1	NITte4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHtWWFKSzVyPUCuPFExOjNizszN	NFT3[FJUSU6JRWK=
PSN1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvHR\|dKSzVyPUCuPVYyQTZizszN	MnvBV2FPT0WU
UACC-257	M1jHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwOU[0O\|Mh\|ryP	NHrZW4RUSU6JRWK=
RVH-421	M1PabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjUTWM2OD1yLkm3NVgh\|ryP	MV\TRW5ITVJ?
GP5d	NFLEXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyxWGpKSzVyPUCuPVg{ODhizszN	M2C2[nNCVkeHUh?=
TYK-nu	NIHoe\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFwMEOxO\|Ih\|ryP	MVTTRW5ITVJ?
SK-N-AS	M2eySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTFwMEe5OFch\|ryP	M1;tV3NCVkeHUh?=
SW620	M{\yW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjLdop2UUN3ME2xMlE{PTN2IN88US=>	MmfYV2FPT0WU
HuP-T4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rZPWlEPTB;MT6xPFM2QSEQvF2=	MknlV2FPT0WU
A549	M37Zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLHTWM2OD1zLkG5OVc3KM7:TR?=	NX\wUWZWW0GQR1XS
Mewo	NF\5dmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPZd3l2UUN3ME2xMlIxOjd4IN88US=>	MnPHV2FPT0WU
ONS-76	M{C3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3OyNGlEPTB;MT6yNlA1QSEQvF2=	NFf5N2xUSU6JRWK=
SK-MEL-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwMkO0NVkh\|ryP	MYPTRW5ITVJ?
RCM-1	NH7TTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIKwfpNKSzVyPUGuNlQxPDdizszN	M4D0[HNCVkeHUh?=
H-EMC-SS	NHzvXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwMkm2NFgh\|ryP	NFTyR\|hUSU6JRWK=
NCI-H2291	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTFwM{K1N\|Yh\|ryP	NF\DdZZUSU6JRWK=
SW1463	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXLTWM2OD1zLkOzO\|IyKM7:TR?=	NFfKUHRUSU6JRWK=
LS-411N	NH;DNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nyO2lEPTB;MT60NFUyPyEQvF2=	NV;FZ4s1W0GQR1XS
BV-173	M2LjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTFwNESwNVUh\|ryP	M1rs[XNCVkeHUh?=
LS-513	NXHUTWtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rRRmlEPTB;MT60OVE6OiEQvF2=	NHjFfXZUSU6JRWK=
LoVo	M4i1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTFwNE[zPVkh\|ryP	MnHlV2FPT0WU
HO-1-N-1	NFfOSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LmPWlEPTB;MT61NVY{PCEQvF2=	MXTTRW5ITVJ?
ML-2	NVPUZ5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTFwNUK4Olgh\|ryP	NWPzNXJlW0GQR1XS
NCI-H1437	M2KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnZeXhKSzVyPUGuOVUzPzVizszN	NYrKOlB{W0GQR1XS
SW1116	M4HzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknwTWM2OD1zLkW2N\|k5KM7:TR?=	M4j1THNCVkeHUh?=
A4-Fuk	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrKNI9DUUN3ME2xMlU4ODR3IN88US=>	M4jG[3NCVkeHUh?=
HD-MY-Z	NXvhUYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnRU4p4UUN3ME2xMlU4Ozd4IN88US=>	MUDTRW5ITVJ?
SK-MEL-2	NG\n[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv2SWhyUUN3ME2xMlU4PDV7IN88US=>	NEXlZZhUSU6JRWK=
RT-112	NXzsTnBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\4dotKSzVyPUGuOVg6PTJizszN	NX\LWItIW0GQR1XS
COLO-829	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;id\|JKSzVyPUGuOlIzOzJizszN	NHvJSlVUSU6JRWK=
OVCAR-5	M{jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHOR25KSzVyPUGuO\|c3QDdizszN	NWrpenVxW0GQR1XS
NB69	M1TQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWmyUJpOUUN3ME2xMlc5PDZ7IN88US=>	NHv6T2VUSU6JRWK=
NCI-H292	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwOE[2PVkh\|ryP	Mn\iV2FPT0WU
LOXIMVI	NICwbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYOwVlZ2UUN3ME2xMlg6PDJ5IN88US=>	MVXTRW5ITVJ?
BPH-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDWZWJxUUN3ME2xMlg6PTlzIN88US=>	NXHIXIVQW0GQR1XS
A375	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTFwOEm3NVQh\|ryP	MoDaV2FPT0WU
LCLC-97TM1	NWjae2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3oTWM2OD1zLkmyNlU3KM7:TR?=	NXTaOIk2W0GQR1XS
RXF393	NXTGVYNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDBTWM2OD1zLkm3PFg4KM7:TR?=	MXrTRW5ITVJ?
HCC70	NV;NZWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV34[JVZUUN3ME2yMlAzPDJ4IN88US=>	MVHTRW5ITVJ?
EM-2	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTJwMEexPVgh\|ryP	NU\TSVRlW0GQR1XS
MZ2-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;FbYxWUUN3ME2yMlEyOTJ5IN88US=>	Mny5V2FPT0WU
HN	M3rk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJwMU[yO\|gh\|ryP	MYTTRW5ITVJ?
A2058	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILJcVZKSzVyPUKuNVkzPzlizszN	MUHTRW5ITVJ?
NB7	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorTTWM2OD1{LkO0NFg3KM7:TR?=	M3LIRnNCVkeHUh?=
DOK	M1HYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHRTWM2OD1{LkO1O\|c{KM7:TR?=	MX\TRW5ITVJ?
CAL-27	M2nPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnHc\|RKSzVyPUKuN\|kzOzZizszN	NF3QUIlUSU6JRWK=
BB65-RCC	NHzJNplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnjTWM2OD1{LkSwOlc1KM7:TR?=	Mny1V2FPT0WU
RD	NFvjTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P6Z2lEPTB;Mj60OFczOyEQvF2=	NID2blRUSU6JRWK=
KNS-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XKc2lEPTB;Mj61NVE3PCEQvF2=	M3rre3NCVkeHUh?=
EW-13	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDuVGJKSzVyPUKuOVY{OzlizszN	M3;rWHNCVkeHUh?=
DB	NY\wXoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nCXmlEPTB;Mj61PFc5QCEQvF2=	NGe3RWdUSU6JRWK=
HCC2218	NXTrT3VLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnZOXEzUUN3ME2yMlY1Pzd6IN88US=>	NVHuNlFuW0GQR1XS
L-363	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zwbGlEPTB;Mj63OFM4KM7:TR?=	M2rqVHNCVkeHUh?=
CHL-1	NXrrSoZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTJwOEC3PFUh\|ryP	NX3nb5JCW0GQR1XS
BFTC-905	M3TSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfNbohuUUN3ME2yMlgzPTNizszN	MmLJV2FPT0WU
HCE-T	M330Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXxelFKSzVyPUKuPFMzPjRizszN	MUnTRW5ITVJ?
COLO-792	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfPUnBKSzVyPUKuPFQxOjdizszN	NF;CeYxUSU6JRWK=
LB2241-RCC	NWDib\|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPNNXNPUUN3ME2yMlg2QDl\|IN88US=>	Mnr6V2FPT0WU
CAL-39	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHYblRKSzVyPUKuPFk6QTlizszN	MYjTRW5ITVJ?
T-24	NFvR[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJwOUGxNVIh\|ryP	NY\E[JRCW0GQR1XS
NCI-H727	NWf3RYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XvOmlEPTB;Mj65NVc6PiEQvF2=	M2jNfHNCVkeHUh?=
Ca9-22	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOycZBRUUN3ME2yMlk4OjV3IN88US=>	MoPDV2FPT0WU
MIA-PaCa-2	NG\HbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTNwMEC3PFEh\|ryP	NFPGVm5USU6JRWK=
HT-1080	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTNwMEG5PVch\|ryP	M3\xNnNCVkeHUh?=
D-423MG	M2Swd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXhPG9KSzVyPUOuNFc4PTNizszN	NVjDVopLW0GQR1XS
LAMA-84	M1TCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDNTVZqUUN3ME2zMlE{PThizszN	NGLqUG5USU6JRWK=
SW780	NG\6eoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\RWmlEPTB;Mz6xOFIzQSEQvF2=	NXvwS2FTW0GQR1XS
KU-19-19	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjQXpFUUUN3ME2zMlE4ODN2IN88US=>	NEHQOYpUSU6JRWK=
COLO-741	NYPP[ZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNwMUi2O\|Mh\|ryP	NU\nOFRWW0GQR1XS
HSC-3	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\BO2lEPTB;Mz6yN\|E2OSEQvF2=	NVjGS\|F2W0GQR1XS
SN12C	M{LyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HxPWlEPTB;Mz6yOFcxOSEQvF2=	M1LZSnNCVkeHUh?=
786-0	NHvpZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTNwMkeyOFMh\|ryP	MkPWV2FPT0WU
GAK	M1TFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTNwM{K1OlEh\|ryP	M4\tTHNCVkeHUh?=
PANC-03-27	NVnzcVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTLb\|FMUUN3ME2zMlM2ODR3IN88US=>	NIjuSYZUSU6JRWK=
CTB-1	NIXxXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnhV3JKSzVyPUOuOFcxPDdizszN	NWGyNVg1W0GQR1XS
A427	NIfkWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnZU49lUUN3ME2zMlU6PTV4IN88US=>	NEDoWGNUSU6JRWK=
EGI-1	M2OzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LwT2lEPTB;Mz62NFU5OyEQvF2=	MWPTRW5ITVJ?
U-2-OS	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTNwNkeyOVYh\|ryP	M2DKTHNCVkeHUh?=
NCI-SNU-5	Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrQV4l{UUN3ME2zMlY4PzNizszN	NVvxSFV4W0GQR1XS
SK-LU-1	NHPrTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NISxdXRKSzVyPUOuOlg4QThizszN	NHnRSmZUSU6JRWK=
697	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\iUItKSzVyPUOuOlk3ODNizszN	MXXTRW5ITVJ?
HPAF-II	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTNwN{W0PUDPxE1?	NW\NeotXW0GQR1XS
NCI-H2087	MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3DTWM2OD1\|Lki0OlczKM7:TR?=	NYPUU3FtW0GQR1XS
SK-MEL-3	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXqVpZKSzVyPUOuPFUyPTRizszN	M2myW3NCVkeHUh?=
CGTH-W-1	NVjYOHIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3E[3hKSzVyPUOuPFU4OjVizszN	M2\PR3NCVkeHUh?=
8505C	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rpUWlEPTB;Mz65NFA4QCEQvF2=	MX;TRW5ITVJ?
GAMG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTRwMEKzO\|ch\|ryP	MV7TRW5ITVJ?
SW626	M4T0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXr0PYJWUUN3ME20MlA1PDhizszN	NVXk[FV7W0GQR1XS
CAL-62	NVz4eIRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTwTWM2OD12LkC3OFMh\|ryP	NF;VNohUSU6JRWK=
MHH-PREB-1	NWXDS\|BqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTRwMUKxNVEh\|ryP	NULsdJJIW0GQR1XS
RPMI-7951	NIj5SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPwdFdZUUN3ME20MlI2PTh7IN88US=>	M4e2UnNCVkeHUh?=
HOP-92	M3y4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv5TWM2OD12LkK1Olch\|ryP	MknIV2FPT0WU
MDA-MB-231	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3KTWM2OD12LkK5NlI{KM7:TR?=	MnnhV2FPT0WU
LAN-6	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVznd4ZpUUN3ME20MlMyPjN5IN88US=>	MYTTRW5ITVJ?
ALL-PO	M3K0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DTeWlEPTB;ND6zOlE2PiEQvF2=	NFPrU5BUSU6JRWK=
HH	M{jtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\0c21KSzVyPUSuOFE2QTdizszN	MULTRW5ITVJ?
IGROV-1	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTRwNEWxO\|Eh\|ryP	Ml7mV2FPT0WU
NCI-H358	NVjMdY1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofoTWM2OD12LkS1N\|g2KM7:TR?=	NVTmN4JEW0GQR1XS
NB5	M{DmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf3U3R7UUN3ME20MlYxOzZ7IN88US=>	MVrTRW5ITVJ?
NCI-H747	NU\oOItQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjGfZNQUUN3ME20MlY5QDB5IN88US=>	NFXLS41USU6JRWK=
NH-12	NXj5NY5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTFUJZ7UUN3ME20MlcyPjJ3IN88US=>	NXvrfm46W0GQR1XS
LB1047-RCC	M3nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTRwN{O4NVUh\|ryP	M{\Ke3NCVkeHUh?=
EFO-27	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1K4b2lEPTB;ND63PFY3PyEQvF2=	NWTmToNEW0GQR1XS
EPLC-272H	Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\IVlZKSzVyPUSuPVk3PjlizszN	M2PCcnNCVkeHUh?=
CAL-54	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4HicmlEPTB;NT6wNlY6PSEQvF2=	NIDwPHNUSU6JRWK=
H4	M2C3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\vSoxmUUN3ME21MlA1OjV3IN88US=>	M1Ps[nNCVkeHUh?=
MOLT-13	NWjvXYtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTVwME[3O\|Yh\|ryP	M1v0TnNCVkeHUh?=
CAL-33	NF7VO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEToWHZKSzVyPUWuNVI{OTdizszN	MnrLV2FPT0WU
23132-87	NETMTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\lTWM2OD13LkG2PFczKM7:TR?=	Mm\VV2FPT0WU
UM-UC-3	MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTVwMUiwOFch\|ryP	NHfib2dUSU6JRWK=
HuH-7	NEK4NI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTVwMkexOFch\|ryP	NWrHXo83W0GQR1XS
BCPAP	M{HCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fJdmlEPTB;NT6zNlk3QSEQvF2=	NVHvV\|F7W0GQR1XS
AsPC-1	NG\L[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDHXWVKSzVyPUWuN\|Y4PjNizszN	MWTTRW5ITVJ?
NCI-H1155	NUCwWnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPXfmZKSzVyPUWuOFAxPTFizszN	M1X1PXNCVkeHUh?=
GT3TKB	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHiOpdpUUN3ME21MlQ3PTl6IN88US=>	NXnFVYJWW0GQR1XS
HCC2998	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXG3VFdKUUN3ME21MlQ6OTB7IN88US=>	NIHoPGhUSU6JRWK=
NUGC-3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLU[VZKSzVyPUWuOFk{ODJizszN	MX;TRW5ITVJ?
Hs-578-T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T5d2lEPTB;NT61N\|c6PCEQvF2=	NIDGenhUSU6JRWK=
FADU	MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWqyXWdyUUN3ME21MlU2PzJ4IN88US=>	MnzuV2FPT0WU
NBsusSR	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi1TWM2OD13LkW3NVU2KM7:TR?=	M3;WVnNCVkeHUh?=
ME-180	NW\zUmFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTVwNUiwPVIh\|ryP	NYDT[5RnW0GQR1XS
SW1710	M1PBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy0Ooc5UUN3ME21MlYyPjV2IN88US=>	MnP3V2FPT0WU
HuP-T3	Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrPTWM2OD13Lk[yNFI6KM7:TR?=	M{fwRXNCVkeHUh?=
HOS	M1:4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlX2TWM2OD13Lk[yPVI{KM7:TR?=	NEHybVFUSU6JRWK=
PA-1	NYK3TZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLZVZVKSzVyPUWuOlQzPjVizszN	NIqyc25USU6JRWK=
LU-99A	M3fQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37Ib2lEPTB;NT62OlQ2OSEQvF2=	NF;BenVUSU6JRWK=
RS4-11	NWDST5l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PMVGlEPTB;NT62Olc4PSEQvF2=	NVuydpJ1W0GQR1XS
TE-8	NEDNfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTVwNki1N\|ch\|ryP	NIDOeY9USU6JRWK=
RERF-LC-MS	M3nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXFTWM2OD13Lk[4PFA{KM7:TR?=	NFPMW2tUSU6JRWK=
MEL-JUSO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHETWM2OD13LkezO\|gh\|ryP	MYHTRW5ITVJ?
SK-MES-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTVwOEO1Nlgh\|ryP	M4Lj[XNCVkeHUh?=
D-263MG	NGfzclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XZcmlEPTB;NT64PFM2OSEQvF2=	NGnjeJJUSU6JRWK=
NB10	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\M[mlEPTB;NT64PVQ3KM7:TR?=	Mly5V2FPT0WU
SK-HEP-1	NY[2VW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NID5PFhKSzVyPUWuPVM1PzFizszN	M4\NfHNCVkeHUh?=
HT-29	NY[2WHVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHqW2hnUUN3ME21Mlk5OTF6IN88US=>	NF:1ZW5USU6JRWK=
KYSE-140	M4Pjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTZwMEKxPFIh\|ryP	NX[2ZodCW0GQR1XS
NCI-H1666	NXvqdZBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL3OnJ7UUN3ME22MlA5PDZzIN88US=>	NYnYTVFDW0GQR1XS
NCI-H1304	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzLWI1PUUN3ME22MlE6QTRizszN	MUTTRW5ITVJ?
RPMI-8866	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7M[oM6UUN3ME22MlIyOzF\|IN88US=>	Ml;HV2FPT0WU
MV-4-11	NEHVUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXOelR3UUN3ME22MlI{OTl7IN88US=>	M1G1eHNCVkeHUh?=
A431	NGrCTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfkc5BKSzVyPU[uNlQzQTZizszN	NV3ieWtWW0GQR1XS
PANC-10-05	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTZwMkizOlMh\|ryP	M1POTHNCVkeHUh?=
TK10	NV;lRotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXKdGZDUUN3ME22MlMzPjB2IN88US=>	Mn;NV2FPT0WU
NCI-H1975	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:2VGlEPTB;Nj60O\|IyPSEQvF2=	M2jIZXNCVkeHUh?=
A172	NHHMU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjWXoVKSzVyPU[uOFkyPzZizszN	Mk\FV2FPT0WU
D-566MG	NGDKSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\sTWM2OD14LkW0N\|A{KM7:TR?=	NHm2fGdUSU6JRWK=
NCI-H2122	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;MTG9KSzVyPU[uOlE2OjhizszN	NGX1cJFUSU6JRWK=
COR-L105	NGH1TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHDTWM2OD14Lk[1Nlc2KM7:TR?=	NU[5VpFPW0GQR1XS
AN3-CA	NIHRVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHVUoJKSzVyPU[uOlg3PDFizszN	MmP1V2FPT0WU
Calu-6	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\PXo1KSzVyPU[uO\|k3QThizszN	NEXEZmlUSU6JRWK=
HCT-116	NInpcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnVVFZ4UUN3ME22MlgyOjZ2IN88US=>	MWrTRW5ITVJ?
MHH-NB-11	NGLHe4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\MbmFHUUN3ME22Mlg2ODB{IN88US=>	NF3HXpRUSU6JRWK=
MFE-280	NV74eHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETY[VVKSzVyPU[uPFU6QDNizszN	MVvTRW5ITVJ?
SW1088	NGS0e2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTZwOUG5NVMh\|ryP	M3HBZ3NCVkeHUh?=
SW48	M2\GXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjjb2hKSzVyPU[uPVQ2OSEQvF2=	NY[wVoNSW0GQR1XS
HuCCT1	M3faZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrpc3RpUUN3ME23MlAyODN5IN88US=>	M3;KPHNCVkeHUh?=
ACHN	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[zUFVKSzVyPUeuNFI6PDNizszN	NX3ve2dJW0GQR1XS
8305C	NE\6OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXR[49KSzVyPUeuNFk6QTVizszN	MkKxV2FPT0WU
DoTc2-4510	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfOVJVKSzVyPUeuNVIyPSEQvF2=	M2\tcXNCVkeHUh?=
COR-L23	M16zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXPTWM2OD15LkK0OFIh\|ryP	Mni2V2FPT0WU
SK-MEL-30	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTdwMkWwPFMh\|ryP	MXvTRW5ITVJ?
BE-13	MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTdwM{O4N\|Qh\|ryP	NX64UHM4W0GQR1XS
GR-ST	NFfoe2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DVSGlEPTB;Nz60NFE4PCEQvF2=	MWDTRW5ITVJ?
LU-135	NULTXIg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG0TWM2OD15LkW1PVM6KM7:TR?=	NXLsbHlNW0GQR1XS
U-266	NHfZdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTdwNU[yPFYh\|ryP	MVvTRW5ITVJ?
NCI-H1355	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTdwNUi2N\|Uh\|ryP	NGXN[2tUSU6JRWK=
NB14	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2jRSGlEPTB;Nz62OlY1OiEQvF2=	MXjTRW5ITVJ?
SCC-25	NYPUeoJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnOwTWM2OD15LkewPUDPxE1?	NHHBVGVUSU6JRWK=
COLO-678	M2\zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTdwN{GwO\|Yh\|ryP	NFX0NndUSU6JRWK=
TGBC1TKB	M1HiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;hN2lKSzVyPUeuPFk{QThizszN	M33sN3NCVkeHUh?=
IST-MEL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\1[VMxUUN3ME24MlAxPDB4IN88US=>	M{m2TnNCVkeHUh?=
ECC10	NWfYclJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzHTWM2OD16LkCzN\|k2KM7:TR?=	MX3TRW5ITVJ?
EW-16	NG\JS\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRThwMEi0OFUh\|ryP	M4nLcnNCVkeHUh?=
DOHH-2	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjkS4w4UUN3ME24MlIxODl3IN88US=>	M2HOeHNCVkeHUh?=
NCI-H1581	M3vtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn3NItKSzVyPUiuNlY{OjNizszN	M4HGZXNCVkeHUh?=
TE-5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUj6T5F4UUN3ME24MlQzPDJ7IN88US=>	NVTXXY5pW0GQR1XS
CAKI-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLRTWM2OD16LkW3NlIzKM7:TR?=	M1Hm[HNCVkeHUh?=
A673	M1;keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHhTWM2OD16Lk[zNlAzKM7:TR?=	M3;KbXNCVkeHUh?=
CAL-12T	NHXjdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULacJhGUUN3ME24MlY2PzV\|IN88US=>	MUPTRW5ITVJ?
DBTRG-05MG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRThwN{S4OVkh\|ryP	NWKyWYFDW0GQR1XS
SK-N-FI	NEHEeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn4WZFKSzVyPUiuPFE{PzlizszN	NU\qV3pUW0GQR1XS
K-562	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LXfGlEPTB;OD64N\|k2PyEQvF2=	NVPyNHJkW0GQR1XS
SBC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRThwOE[2OFUh\|ryP	NEfoUI1USU6JRWK=
ES4	NF\3U3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnPTWM2OD16Lki2PFg1KM7:TR?=	MVTTRW5ITVJ?
MS-1	NX7HdJpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRThwOEe1NVch\|ryP	NWXxOmxnW0GQR1XS
RKO	Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnhTWM2OD16Lki5NFU4KM7:TR?=	NYDrcWM4W0GQR1XS
NCI-H1693	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\2SFFvUUN3ME24MlkzOTdizszN	NWjT[3p{W0GQR1XS
SW954	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXzUnF6UUN3ME24Mlk3QTd6IN88US=>	MoS5V2FPT0WU
SK-UT-1	Mn;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;rcXJKSzVyPUiuPVc3QDNizszN	NYHiOJd7W0GQR1XS
T98G	NXvpWXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\rUXdpUUN3ME24Mlk6QDR4IN88US=>	NH63T49USU6JRWK=
NCI-H2126	NYPqVFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfJcYZIUUN3ME25MlAxQDJ4IN88US=>	MYLTRW5ITVJ?
TE-12	NGnLO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTlwMEOzOlch\|ryP	NH21fWhUSU6JRWK=
DK-MG	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXjSY1KSzVyPUmuNlEyQTFizszN	MVrTRW5ITVJ?
MEG-01	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H1S2lEPTB;OT6yOFk{OSEQvF2=	MVrTRW5ITVJ?
HCC1937	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2X2S2lEPTB;OT6yPVA6OSEQvF2=	NXLrVHo2W0GQR1XS
MKN45	NFexeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfNXmJKSzVyPUmuOFUxPjVizszN	MkXpV2FPT0WU
NCI-H1792	NILGSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHVTWM2OD17LkS1NlE6KM7:TR?=	NUHIWFg1W0GQR1XS
SW1417	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Dn[2lEPTB;OT61Olg{PyEQvF2=	MXzTRW5ITVJ?
639-V	NH3WPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmr1TWM2OD17Lk[0N\|g5KM7:TR?=	Mn\0V2FPT0WU
P30-OHK	M1SyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnWzTWM2OD17Lk[1N\|E3KM7:TR?=	Ml7DV2FPT0WU
YKG-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTlwN{WwN\|Mh\|ryP	M3rTPHNCVkeHUh?=
KGN	M2\hXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTlwOEO3PVUh\|ryP	MULTRW5ITVJ?
MSTO-211H	NGDUOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[2XpF2UUN3ME25Mlk2PTJ7IN88US=>	Mm\OV2FPT0WU
NCI-H1573	NFj5b\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rZUGlEPTB;MUCuNVU4PCEQvF2=	NFjJXYpUSU6JRWK=
NCI-H720	M4LzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Poc2lEPTB;MUCuNVk5QSEQvF2=	M{PTXXNCVkeHUh?=
KARPAS-45	M1TxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nQV2lEPTB;MUCuNlc6PSEQvF2=	Mn3sV2FPT0WU
MDA-MB-175-VII	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTFyLkS4JO69VQ>?	NXTHUVlNW0GQR1XS
SK-NEP-1	NHSxOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnOzTWM2OD1zMD60PVgyKM7:TR?=	M4XaVXNCVkeHUh?=
MKN28	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTFyLkWxPEDPxE1?	NX[yelhmW0GQR1XS
KYSE-520	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTFyLkWyJO69VQ>?	NGTiW5BUSU6JRWK=
KE-37	NX3pZ\|FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPyTWM2OD1zMD61NlczKM7:TR?=	MnPVV2FPT0WU
VA-ES-BJ	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTFyLkW2O{DPxE1?	M4HETHNCVkeHUh?=
CCRF-CEM	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPYfnE4UUN3ME2xNE42Pjh2IN88US=>	MU\TRW5ITVJ?
GMS-10	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7ieFJKSzVyPUGwMlYxQTRizszN	NF[4d41USU6JRWK=
NCI-H1623	NHPiUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW3XYM2UUN3ME2xNE43Ozd7IN88US=>	MVzTRW5ITVJ?
NEC8	NVrHWW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TRcmlEPTB;MUCuO\|c4OyEQvF2=	M3fXdHNCVkeHUh?=
MOLT-16	M1vMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrS[JBKSzVyPUGwMlgyOTNizszN	NXnzc4ZlW0GQR1XS
DJM-1	NWHFfo46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfoUG5KSzVyPUGxMlA{PzlizszN	MVXTRW5ITVJ?
U251	NHLDWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrJdGFnUUN3ME2xNU4xPDJizszN	MmfPV2FPT0WU
SBC-5	NXSzTGdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfURpFRUUN3ME2xNU4yPDZ5IN88US=>	NHS3doZUSU6JRWK=
SW756	M4T3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDHTVlzUUN3ME2xNU4zOTV2IN88US=>	NHX1d\|NUSU6JRWK=
KS-1	NYHtS\|htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHaTnpRUUN3ME2xNU4zPjF7IN88US=>	MXfTRW5ITVJ?
SF295	M3TDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTjWYFKSzVyPUGxMlMyODRizszN	M3TsN3NCVkeHUh?=
YH-13	NGntOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFzLkOyOlch\|ryP	MmjsV2FPT0WU
SW837	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\LcVhrUUN3ME2xNU4{PTB4IN88US=>	NWHOWWhNW0GQR1XS
KYSE-450	M2PuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDhO5NSUUN3ME2xNU41ODV5IN88US=>	MmS3V2FPT0WU
KYSE-180	NEG5SWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofDTWM2OD1zMT60PFIh\|ryP	NInIe2ZUSU6JRWK=
S-117	NUDVNHczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFzLkS4PVYh\|ryP	MmTQV2FPT0WU
KOSC-2	NV75UIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXi4[ZZWUUN3ME2xNU43OjJ{IN88US=>	MnvZV2FPT0WU
KYSE-270	M17oPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4npSWlEPTB;MUGuPFc1PSEQvF2=	NF22U4RUSU6JRWK=
D-336MG	M2q2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfCSYxKSzVyPUGxMlkxPzVizszN	NF:3[oxUSU6JRWK=
KALS-1	M3;UXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrvWmRxUUN3ME2xNk4xODF4IN88US=>	NV76[G83W0GQR1XS
LB373-MEL-D	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj1dJBwUUN3ME2xNk4xPTN\|IN88US=>	NYjYNJlmW0GQR1XS
HLE	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHuyO2NKSzVyPUGyMlA2QDVizszN	NXPGZ45YW0GQR1XS
SJSA-1	M3zRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTF{LkC3N\|Uh\|ryP	MmGzV2FPT0WU
SW1990	NFyxbZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPublhKSzVyPUGyMlA6OTFizszN	NWPaO5B7W0GQR1XS
NOS-1	M1PQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfJUY9bUUN3ME2xNk4yOzV{IN88US=>	M{\hRXNCVkeHUh?=
GI-ME-N	NHfmSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrMXWRKSzVyPUGyMlIyPjNizszN	NILGXWxUSU6JRWK=
NCI-H1703	NUT1cJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHkWXBKSzVyPUGyMlI3OTZizszN	MYXTRW5ITVJ?
ES7	M3rRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\IUWlEPTB;MUKuNlczPCEQvF2=	M{\ORnNCVkeHUh?=
KYSE-510	NVK3VHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rFeWlEPTB;MUKuOVA4QSEQvF2=	M3;vfXNCVkeHUh?=
BHY	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3roWWlEPTB;MUKuOVMxPyEQvF2=	NV\JZoJrW0GQR1XS
TCCSUP	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF[wPYRKSzVyPUGyMlU4PTdizszN	NFvxc3VUSU6JRWK=
HSC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfzbYpKSzVyPUGyMlU6QTZizszN	MUjTRW5ITVJ?
BEN	NI\4R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnLSlFHUUN3ME2xNk43OTR\|IN88US=>	M1u0VHNCVkeHUh?=
769-P	NGXDPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTFTWM2OD1zMj63PVI1KM7:TR?=	MXvTRW5ITVJ?
HT	NWrT[oo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\RTWM2OD1zMj64N\|Q3KM7:TR?=	M2fOfnNCVkeHUh?=
LXF-289	M4PiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;mfo5KSzVyPUGyMlk2OzFizszN	M3S2RnNCVkeHUh?=
OVCAR-3	M4jz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTQVnBKSzVyPUGyMlk2PjdizszN	M1v0NHNCVkeHUh?=
ATN-1	NEfOOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTF\|LkCxPFQh\|ryP	NHezSHlUSU6JRWK=
8-MG-BA	NG\ifZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTF\|LkC0OVUh\|ryP	Mlj5V2FPT0WU
SW13	NFfpU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWWxNGRTUUN3ME2xN{4yOTZ3IN88US=>	Mn\rV2FPT0WU
NCI-H1092	NF\ySZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHEOVZ7UUN3ME2xN{4yPjJizszN	M1OzNnNCVkeHUh?=
OAW-42	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\jTWM2OD1zMz6xPVM4KM7:TR?=	MkTkV2FPT0WU
NCI-H2452	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXST\|ZKSzVyPUGzMlIyPzVizszN	M4e3R3NCVkeHUh?=
CAPAN-1	M3TZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:1N5dnUUN3ME2xN{42PTF2IN88US=>	NVnaPVlIW0GQR1XS
NCI-H2009	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTF\|LkW5NVkh\|ryP	MojxV2FPT0WU
SF268	M3HofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfq[pFKSzVyPUGzMlY{OjZizszN	M{CxTXNCVkeHUh?=
GCIY	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf3TWM2OD1zMz62PVI4KM7:TR?=	M1fSOnNCVkeHUh?=
OS-RC-2	NX7sb\|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTF\|Lkm1NFEh\|ryP	Ml22V2FPT0WU
GCT	M2PwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTF\|Lkm2PVch\|ryP	NXnzemdpW0GQR1XS
NB17	M1\hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TY[WlEPTB;MUSuNFg2KM7:TR?=	M3fSeHNCVkeHUh?=
NCI-H2030	M{Xn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTkXG8xUUN3ME2xOE4yPDZ3IN88US=>	MoHUV2FPT0WU
HC-1	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzoV45FUUN3ME2xOE4zODh5IN88US=>	NUHy[FlGW0GQR1XS
QIMR-WIL	M2TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTF2LkO0NVIh\|ryP	M37kVnNCVkeHUh?=
Capan-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mly5TWM2OD1zND6zO\|E1KM7:TR?=	NIPKd3ZUSU6JRWK=
BALL-1	M1Gyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXmXVBKSzVyPUG0MlQ3PjVizszN	MVnTRW5ITVJ?
LS-1034	NX3MUHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF2Lk[xOVIh\|ryP	NILnSZhUSU6JRWK=
U-118-MG	NXnMdpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj1c4ZKSzVyPUG0MlY{OSEQvF2=	MWPTRW5ITVJ?
NCI-H630	M3XoPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTF2Lk[1Olgh\|ryP	NXTSNYM3W0GQR1XS
OVCAR-8	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrQTWM2OD1zND63NlAyKM7:TR?=	MmDJV2FPT0WU
NCI-H2347	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTF2LkiyN{DPxE1?	NYK2S5AxW0GQR1XS
BT-549	M2jKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX21dG1bUUN3ME2xOE45Ojh2IN88US=>	M2HLbXNCVkeHUh?=
LB831-BLC	NWPmb2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnKSFJKSzVyPUG0Mlg6OzRizszN	MXPTRW5ITVJ?
NCI-H661	M3vKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\VTWM2OD1zND65OVkh\|ryP	MnnLV2FPT0WU
MKN7	NGThflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTF3LkCwPVMh\|ryP	M2\ZbHNCVkeHUh?=
U-87-MG	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmS2TWM2OD1zNT6wPFk4KM7:TR?=	MlTtV2FPT0WU
OVCAR-4	NHzrVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3L6WWlEPTB;MUWuNVQzPCEQvF2=	NIr6V5pUSU6JRWK=
OE33	NGTndoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnwTWM2OD1zNT6xO\|EyKM7:TR?=	M{XiXnNCVkeHUh?=
EC-GI-10	M3HqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nUOWlEPTB;MUWuNlM2PyEQvF2=	MVfTRW5ITVJ?
AM-38	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTF3LkK3NVch\|ryP	M4XSfXNCVkeHUh?=
NCI-H1563	M3rSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vndGlEPTB;MUWuN\|Q6KM7:TR?=	NIrOZ3pUSU6JRWK=
SCC-4	M4jOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rBR2lEPTB;MUWuOFExOyEQvF2=	NWrCc3R{W0GQR1XS
Detroit562	M3n6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTF3LkS1OFch\|ryP	MlHBV2FPT0WU
PC-14	M3vjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTF3LkS4OlYh\|ryP	MkTHV2FPT0WU
ES3	MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjHPIV5UUN3ME2xOU42OzZizszN	MYfTRW5ITVJ?
OCI-AML2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTF3Lke2NVQh\|ryP	MV\TRW5ITVJ?
LU-134-A	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1qwU2lEPTB;MUWuPVAyQCEQvF2=	MknrV2FPT0WU
SAS	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojCTWM2OD1zNT65N\|c{KM7:TR?=	M362T3NCVkeHUh?=
TGBC11TKB	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTF3Lkm0NVQh\|ryP	NELWXYFUSU6JRWK=
HOP-62	NYnnNWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHOO\|BjUUN3ME2xOU46PTl5IN88US=>	MXTTRW5ITVJ?
G-401	NXPDVpVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTF3Lkm2OFkh\|ryP	MX;TRW5ITVJ?
NCI-H28	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojtTWM2OD1zNj6wPFU3KM7:TR?=	NXHVcVlTW0GQR1XS
A204	M{PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvUe5c6UUN3ME2xOk4zODB4IN88US=>	NVm1Ooo{W0GQR1XS
NCI-H1299	NFPz[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrN[YZsUUN3ME2xOk4zOjlzIN88US=>	MmrMV2FPT0WU
VMRC-RCZ	M4Lacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3nb4ZDUUN3ME2xOk4zPTl{IN88US=>	NHTRc25USU6JRWK=
BxPC-3	M3P0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT4XVlrUUN3ME2xOk4zQDV4IN88US=>	NX\jWFE4W0GQR1XS
NCI-H2228	M4XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO0TpZxUUN3ME2xOk42OTV6IN88US=>	NIjWWVlUSU6JRWK=
NCI-H23	NInMWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTF4Lk[wO\|gh\|ryP	NVnFPVF6W0GQR1XS
NKM-1	NVyxUXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrNTWM2OD1zNz6wNVg6KM7:TR?=	NXjvcmVFW0GQR1XS
KYSE-70	NUjjXpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX1XYpKSzVyPUG3MlI5QSEQvF2=	NILVcYRUSU6JRWK=
BB49-HNC	NHq0PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;yVmlEPTB;MUeuOVY5PiEQvF2=	M4i3RnNCVkeHUh?=
SCC-15	M{PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzMU\|JKSzVyPUG3Mlg1PzNizszN	NF;HenNUSU6JRWK=
D-247MG	NVnUSZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTF5LkmyOFch\|ryP	NULMcZo3W0GQR1XS
BB30-HNC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTF6LkCzNVgh\|ryP	M3jJfXNCVkeHUh?=
CAL-85-1	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvYTWM2OD1zOD6xPFA6KM7:TR?=	NYLBPGt7W0GQR1XS
HT-3	M2flfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjzNXdKSzVyPUG4MlM6PzdizszN	Mln2V2FPT0WU
KYSE-410	M{TkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17kcGlEPTB;MUiuOFU4PyEQvF2=	M{LaeXNCVkeHUh?=
SW982	NXSyS3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXFcVJ{UUN3ME2xPE42PjR7IN88US=>	NHnnSWNUSU6JRWK=
SW962	NUfOVopCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXKUZZKSzVyPUG4MlU4ODJizszN	NYq1c5ZJW0GQR1XS
Ramos-2G6-4C10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;NSppNUUN3ME2xPE42QTJ5IN88US=>	NEf4VGZUSU6JRWK=
OC-314	M{HxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fmU2lEPTB;MUiuO\|M5PCEQvF2=	NGTTTGVUSU6JRWK=
LS-123	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHH0NIdKSzVyPUG4Mlc6ODFizszN	Mon4V2FPT0WU
D-502MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTF6LkixN\|kh\|ryP	MkPoV2FPT0WU
RO82-W-1	NUW2bFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;mWVlKSzVyPUG4MlgzQDhizszN	MYHTRW5ITVJ?
HuO9	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LSSWlEPTB;MUmuNVM4QSEQvF2=	M1XFcXNCVkeHUh?=
ETK-1	M4iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTVTWM2OD1zOT6xPFI4KM7:TR?=	Mn3qV2FPT0WU
SNU-387	M4\E[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\nSGlEPTB;MUmuNVg5QSEQvF2=	M4rMeXNCVkeHUh?=
SW1573	MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHDVoNjUUN3ME2xPU4yQTZ7IN88US=>	MXHTRW5ITVJ?
NTERA-S-cl-D1	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF7LkKwNFch\|ryP	MkjhV2FPT0WU
SF126	M{HVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTF7LkO1NFIh\|ryP	MmK3V2FPT0WU
Calu-3	M3zhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\xZmlEPTB;MUmuOFI{PyEQvF2=	MYPTRW5ITVJ?
NCI-H1048	MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJyLkOyOlYh\|ryP	M{DaUHNCVkeHUh?=
NCI-H226	M2\BZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXizTWpnUUN3ME2yNE41Ozl7IN88US=>	M{\Je3NCVkeHUh?=
FTC-133	NXHne\|lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrMZ4pKSzVyPUKwMlQ4ODNizszN	MVfTRW5ITVJ?
SF539	NFTJU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;OWWRKSzVyPUKwMlUyPzJizszN	M4r0enNCVkeHUh?=
TE-6	NXi3Z5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfzWI9KSzVyPUKwMlgxPjdizszN	Ml:yV2FPT0WU
UMC-11	NEG0e3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3ncYRVUUN3ME2yNE46OTZ2IN88US=>	NXHZWm56W0GQR1XS
Becker	NYHDSmdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTNTmtTUUN3ME2yNU4yOTF6IN88US=>	NY[z[YhlW0GQR1XS
KP-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVK4cJhmUUN3ME2yNU4yOTl4IN88US=>	M4nVUHNCVkeHUh?=
ChaGo-K-1	NYnzelZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTJzLkO2Nlch\|ryP	NIrNNG1USU6JRWK=
CFPAC-1	M1fWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7BfG5NUUN3ME2yNU4{QDV6IN88US=>	MXHTRW5ITVJ?
A498	MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDuVYtKSzVyPUKxMlU{OTJizszN	NGTndGlUSU6JRWK=
NCI-H1755	NI[zcpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJzLk[3OFEh\|ryP	NFnGXXJUSU6JRWK=
TI-73	NV;wRmE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37hfmlEPTB;MkKuN\|I5KM7:TR?=	NVrIb\|ZWW0GQR1XS
NCI-H441	NXiwOJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJ{LkW2PFkh\|ryP	NHPLOY5USU6JRWK=
CaR-1	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nKTWlEPTB;MkOuNFIyOyEQvF2=	MkPXV2FPT0WU
HCC1806	NWO3O5VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLjS25RUUN3ME2yN{4xPTh\|IN88US=>	NUnhWJZoW0GQR1XS
SNU-449	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HweGlEPTB;MkOuN\|I6KM7:TR?=	MWDTRW5ITVJ?
EKVX	M3jNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlW2TWM2OD1{Mz6zPVA6KM7:TR?=	NXTMcpNOW0GQR1XS
DMS-114	NV3aT5VVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTJ\|LkW3OlUh\|ryP	NX:3U\|JXW0GQR1XS
A704	MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrTTWM2OD1{Mz62NVA{KM7:TR?=	MX7TRW5ITVJ?
LC-2-ad	NXPjbIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJ\|Lk[xOFch\|ryP	NVfLWYp4W0GQR1XS
VM-CUB-1	NV;wfY41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnH3TWM2OD1{Mz63N\|QyKM7:TR?=	MVzTRW5ITVJ?
PC-3	NGHQNlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTJ2LkC1NlYh\|ryP	M2\NWXNCVkeHUh?=
HEL	NFzFXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PrPGlEPTB;MkSuNFg3PSEQvF2=	M1jRV3NCVkeHUh?=
ABC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PFfGlEPTB;MkSuNlczQSEQvF2=	NGXHcmZUSU6JRWK=
COLO-680N	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn2xTWM2OD1{ND60O\|Y1KM7:TR?=	NGH4T4VUSU6JRWK=
MZ1-PC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ2Lk[4O{DPxE1?	MlqzV2FPT0WU
NCI-H69	MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoG1TWM2OD1{ND63N\|U1KM7:TR?=	MUXTRW5ITVJ?
TE-1	M{P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfhfYUyUUN3ME2yOU4xPDl7IN88US=>	NXfRb\|J3W0GQR1XS
EW-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHjbnNKSzVyPUK1MlEyOyEQvF2=	M3nBUHNCVkeHUh?=
PANC-08-13	M1rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrkS4hKSzVyPUK1MlgyODNizszN	M4H0XnNCVkeHUh?=
NMC-G1	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLDZ4FxUUN3ME2yOk4xODh6IN88US=>	NGTHTFlUSU6JRWK=
BT-20	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfZTWM2OD1{Nj60OVQ{KM7:TR?=	M13vSnNCVkeHUh?=
TGBC24TKB	NWGzbZpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTJ4LkezN\|Eh\|ryP	M{jHNXNCVkeHUh?=
TE-11	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnL3TWM2OD1{Nj65PFk2KM7:TR?=	NI\Jc21USU6JRWK=
ESS-1	M{DpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfPS49KSzVyPUK3MlMzOTZizszN	MX3TRW5ITVJ?
JVM-3	M4DMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoG1TWM2OD1{Nz62OFc2KM7:TR?=	MkXQV2FPT0WU
C3A	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfZTWM2OD1{Nz64OFk3KM7:TR?=	NUjGOJJkW0GQR1XS
MDA-MB-157	M{i1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4i5fmlEPTB;MkeuPFc2OyEQvF2=	NVjCXJJ{W0GQR1XS
KLE	M4rpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJ6LkGwOVgh\|ryP	NEHEXYRUSU6JRWK=
ES1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTJ6LkG4N\|gh\|ryP	M1fmc3NCVkeHUh?=
CAL-120	M{TxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLiTGI3UUN3ME2yPE4{QTl7IN88US=>	MXzTRW5ITVJ?
NCI-N87	M1rJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjnTWM2OD1{OD61NVA2KM7:TR?=	Mn;NV2FPT0WU
RPMI-8226	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzxRlFKSzVyPUK5MlE5PDNizszN	MYrTRW5ITVJ?
COR-L88	M1q3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XuSGlEPTB;MkmuNlQyQSEQvF2=	NVrBOWJ3W0GQR1XS
UACC-893	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTJ7LkOxN\|ch\|ryP	NEnzbXBUSU6JRWK=
C8166	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XVN2lEPTB;MkmuPVk6PiEQvF2=	NFLFWHBUSU6JRWK=
J82	NXXyO3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y3VGlEPTB;M{CuPFE1PyEQvF2=	NG\2XZFUSU6JRWK=
PFSK-1	M3raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTNzLkC2OVkh\|ryP	MWXTRW5ITVJ?
COLO-684	NWTzfXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHeySHZKSzVyPUOxMlQ{PzRizszN	MV;TRW5ITVJ?
CAL-72	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE[z[oNKSzVyPUOxMlU4OjlizszN	MkPlV2FPT0WU
SNB75	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTNzLki5O{DPxE1?	NWfRXpg2W0GQR1XS
MDA-MB-415	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vF[WlEPTB;M{GuPVc3OiEQvF2=	M2fHNXNCVkeHUh?=
SiHa	NVLYT3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f0e2lEPTB;M{KuOFcyOSEQvF2=	M{W2[XNCVkeHUh?=
NCI-H1648	NICxZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX6UnBKSzVyPUOyMlk{PDVizszN	NVriNG1bW0GQR1XS
EFO-21	NV7ZZoVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTqOXpKSzVyPUOzMlAxPSEQvF2=	MoXCV2FPT0WU
HCC38	M1jaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LZb2lEPTB;M{OuN\|g1OSEQvF2=	M3LJ[HNCVkeHUh?=
IA-LM	NEi5OZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3iwb2lEPTB;M{OuO\|g5QSEQvF2=	MmCwV2FPT0WU
CTV-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfhUVFIUUN3ME2zN{46Pzh4IN88US=>	M2KzOXNCVkeHUh?=
NCI-H446	MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTTb\|hKSzVyPUO0MlI3QDlizszN	NFW5ZXlUSU6JRWK=
IST-SL1	NHv0dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrBSYxKSzVyPUO0Mlc1ODhizszN	NVi5dVF6W0GQR1XS
EW-22	NWW4Rmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\jRmlEPTB;M{SuO\|c2QSEQvF2=	NGjKb4JUSU6JRWK=
JEG-3	MlLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIribo5KSzVyPUO2MlE4PjZizszN	NXLOSWpPW0GQR1XS
LU-65	M3;temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK2ZYVKSzVyPUO2MlI6QDVizszN	MYLTRW5ITVJ?
NCI-H596	NVHHbWsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH2yT\|BKSzVyPUO2Mlk2QTFizszN	NFTneHhUSU6JRWK=
KNS-81-FD	Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\IT4cyUUN3ME2zO{4yPDVizszN	MVXTRW5ITVJ?
NCI-H1793	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnITWM2OD1\|Nz63NFg3KM7:TR?=	MV3TRW5ITVJ?
NCI-H460	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPYXWRKSzVyPUO4MlA5PzNizszN	NW\vXoNNW0GQR1XS
MPP-89	NGDDcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HrUWlEPTB;M{muOVg5PiEQvF2=	M2nmPXNCVkeHUh?=
D-542MG	M4f4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH5W4ZKSzVyPUO5Mlg1OzZizszN	MXHTRW5ITVJ?
JAR	NHG5em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTETXVpUUN3ME20NE41PzB3IN88US=>	NFXVPFdUSU6JRWK=
NCI-H209	NILRdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jRXGlEPTB;NECuOlc4KM7:TR?=	MY\TRW5ITVJ?
G-402	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrrZoVsUUN3ME20NU4{QTl\|IN88US=>	NIjYOnNUSU6JRWK=
IST-MES1	NIHq[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXm[Zg3UUN3ME20Nk4yQTN3IN88US=>	MUfTRW5ITVJ?
Daoy	NHrOT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3np[2lEPTB;NEKuOVQ4OSEQvF2=	M2juVXNCVkeHUh?=
EW-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTR\|LkGyNVEh\|ryP	MXLTRW5ITVJ?
Saos-2	M2S4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfGTWM2OD12Mz6xOVM4KM7:TR?=	MXTTRW5ITVJ?
no-10	NXvJNFRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlOxTWM2OD12Mz6xO\|AzKM7:TR?=	MWXTRW5ITVJ?
HCC1395	NHjrbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjFSlJZUUN3ME20N{41PjR2IN88US=>	M4HyfnNCVkeHUh?=
HCE-4	NYnNdotLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTR\|Lke2OlQh\|ryP	NUW0TG4yW0GQR1XS
EW-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLSZphKSzVyPUSzMlgxPDlizszN	NX;ufFV6W0GQR1XS
OCUB-M	NWDF[Gh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvXbFdKSzVyPUS0MlM3OzhizszN	MVjTRW5ITVJ?
IGR-1	NUP2UmI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX74S5RzUUN3ME20OE41OTF3IN88US=>	MVXTRW5ITVJ?
NCI-H1838	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PqcmlEPTB;NESuOFM1QSEQvF2=	Mk\KV2FPT0WU
NCI-H2405	M36ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTR2LkWzOEDPxE1?	MV;TRW5ITVJ?
GB-1	NIPYdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfrPZBSUUN3ME20OE44PDZ\|IN88US=>	M3vVSHNCVkeHUh?=
MG-63	NYTRNpdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHvXHpKSzVyPUS2MlA3QTZizszN	MVnTRW5ITVJ?
KP-N-YN	M2q1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTR4LkS2O\|kh\|ryP	MVrTRW5ITVJ?
no-11	M1jwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m2dWlEPTB;NEeuNFI1PCEQvF2=	MV;TRW5ITVJ?
SW948	NUPqNJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXlcVB3UUN3ME20O{4{Ozd5IN88US=>	MkTUV2FPT0WU
CAMA-1	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M170cmlEPTB;NEeuN\|Q{QCEQvF2=	NF;lcVBUSU6JRWK=
HCC1187	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TCc2lEPTB;NEeuOVEh\|ryP	M3LkNnNCVkeHUh?=
D-392MG	NIf4RW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jjN2lEPTB;NEeuOlUyPiEQvF2=	MlXCV2FPT0WU
647-V	MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2m2b2lEPTB;NEmuN\|QyPCEQvF2=	MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	+ Expand MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	+ Expand Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	+ Expand Animal Models: PTC cells in athymic mice Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Ethanol	14 mg/mL (29.24 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00033384	Completed	Breast Cancer\|Colorectal Cancer\|Lung Cancer\|Pancreatic Cancer	University of Alabama at Birmingham\|National Cancer Institute (NCI)	February 2002	Phase 2
NCT00033384	Completed	Breast Cancer\|Colorectal Cancer\|Lung Cancer\|Pancreatic Cancer	University of Alabama at Birmingham\|National Cancer Institute (NCI)	February 2002	Phase 2
NCT00034827	Completed	Colorectal Neoplasms\|Breast Neoplasms\|Carcinoma Non-Small-Cell Lung\|Pancreatic Neoplasms	Pfizer	January 2002	Phase 2
NCT00034827	Completed	Colorectal Neoplasms\|Breast Neoplasms\|Carcinoma Non-Small-Cell Lung\|Pancreatic Neoplasms	Pfizer	January 2002	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products4

Cobimetinib (GDC-0973, RG7420) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

Features:More potent than PD0325901 or AZD6244.
PD0325901

PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162, ARRY-162, ARRY-438162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Refametinib (RDEA119, Bay 86-9766)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 47 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)

Cited by 47 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD184352 (CI-1040) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)